TICKERNERD
Menu
BHSTBHSTConsumer Defensive · Packaged Foods

BHST Stock Forecast: BioHarvest Sciences, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$1.71
+1.79% on the day

The 4 Wall Street analysts covering BioHarvest Sciences, Inc. hold a median 12-month price target of $11 — +543.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 23 Oct 2026 — in the lower half.

Market cap
$39.0M
Ticker Nerd rank
42/ 100
Median analyst target
$11
Analysts covering
4
Revenue$8.8M+3.8% y/y
Operating income−$2.5M
Net income−$3.7M
Free cash flow−$3.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
+17.1%
YTD
−67.1%
1Y
−85.6%
From 52W high
−85.6%
From 52W low
+17.9%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BHST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioHarvest Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
83
Quality
76
Growth
71
Volatility
69
Issuance
67
Value
47
Revisions
27
Accruals
16
Momentum
2

Size (83): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BHST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BHST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26BHSTHigh $15Median $11Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5Median $11High $15

The green dot is the last close — the median target sits +543.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026Maxim GroupMaintainsBuy$12 → $5.00
12 Aug 2026Roth CapitalMaintainsBuy$10 → $8.00
19 Feb 2026Roth CapitalInitiatesBuy—
19 Feb 2026Roth CapitalInitiatesBuy$10
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024Maxim GroupInitiatesBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—
6 Dec 2024HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BHST appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

BHST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, BioHarvest Sciences, Inc. returned −85.6% against +14.3% for the S&P 500, dividends included.

BHST vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26BHSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BHST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

BioHarvest Sciences, Inc. (BHST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 88% of US stocks

Price / sales
1.1×

Cheaper than 66% of US stocks

Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
−6.6×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
3.8%

Higher than 36% of US stocks

Earnings growth (YoY)
3.8%

Higher than 41% of US stocks

Gross margin
57.5%

Higher than 70% of US stocks

Operating margin
−28.4%

Higher than 20% of US stocks

Net margin
−31.2%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−142.5%

Higher than 10% of US stocks

Return on assets
−11.0%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioHarvest Sciences, Inc. (BHST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioHarvest Sciences, Inc. has a market value of $39.0M and an enterprise value of $38.5M.

  • Revenue in the twelve months to 30 June 2026: $35.5M. The latest quarter grew 3.8% year on year.

  • Net income over the same four quarters: −$11.1M, a −31.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$10.8M.

  • Shares outstanding: 22.7M.

  • Trailing P/E: −2.9×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BioHarvest Sciences, Inc. employs 89 people — $399K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

BHST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
BHSTBioHarvest Sciences, Inc.$39.0M42
BOFBranchOut Food, Inc.$32.6M19
LSFLaird Superfood, Inc.$30.4M21
BRIDBridgford Foods Corp.$49.9M30
CLNNClene, Inc.$55.2M20
JVACoffee Holding Co., Inc.$25.6M96
COOTAustralian Oilseeds Holdings Ltd.$25.5M7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioHarvest Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BHST news & analysis

BioHarvest takes second plant-cell asset to commercial readiness

Proactive Investors · 13 Oct 2026positive

BioHarvest Sciences said Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing. It is the second Botanical Synthesis product to reach this stage, after large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. GRAS process.

Why it matters — The milestone adds a second Botanical Synthesis ingredient to BioHarvest’s portfolio that the company says is ready for commercial licensing.

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Newsfile Corp · 13 Oct 2026positive

BioHarvest Sciences said its proprietary Olive Cell composition has completed development, commercial-scale manufacturing preparation and the applicable self-affirmed GRAS process. The asset is ready for production at the company’s GMP facility and available for licensing and commercialization through its CDMO business.

Why it matters — The milestone highlights a completed path from plant-cell development to commercial readiness and creates a licensing opportunity for BioHarvest’s CDMO business.

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Proactive Investors · 8 Oct 2026positive

BioHarvest Sciences said its Botanical Synthesis platform can produce the next-generation sweetener targeted in its joint development program with Tate & Lyle. Tate & Lyle is seeking to broaden its sweetener range as manufacturers look to reduce sugar and calories while retaining taste and functionality.

Why it matters — The update reports progress toward producing the sweetener being developed in BHST’s program with Tate & Lyle.

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Newsfile Corp · 8 Oct 2026positive

Tate & Lyle and BioHarvest announced a milestone in their next-generation sweetener development programme. The programme demonstrated that BioHarvest’s Botanical Synthesis™ platform can produce the targeted sweetening solution.

Why it matters — The milestone provides an update on BioHarvest’s platform’s ability to support the sweetener development programme with Tate & Lyle.

BioHarvest Sciences launches buyback of up to 5% of shares

Proactive Investors · 29 Sept 2026positive

BioHarvest Sciences' board has authorized a share repurchase program covering up to 5% of its outstanding common shares. The program will be structured as a normal course issuer bid, in line with Canadian practice.

Why it matters — A buyback of this size signals management's confidence in the company and could reduce the number of shares outstanding.

FAQ

Frequently asked questions about BHST stock

What is the BHST stock price forecast for 2026-2027?

The 4 Wall Street analysts covering BioHarvest Sciences, Inc. have a median 12-month price target of $11, with estimates ranging from $5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BHST stock a buy right now?

Of the 4 analysts covering BioHarvest Sciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioHarvest Sciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BHST?

As at 23 Oct 2026, BioHarvest Sciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).

Will BHST stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +543.3% from the last close, and Ticker Nerd's factor model ranks BioHarvest Sciences, Inc. 42 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BHST stock forecast for 2030?

No analyst covering BioHarvest Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $15 over the next 12 months.

How has BHST stock performed over the past year?

BioHarvest Sciences, Inc. returned -85.6% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioHarvest Sciences, Inc. do?

BioHarvest Sciences Inc. is a biotechnology company focused on Botanical Synthesis, a proprietary platform used to produce plant-based compounds without growing the underlying plant.

What is the latest news on BHST?

The most recent item we track (Proactive Investors, 13 Oct 2026): "BioHarvest takes second plant-cell asset to commercial readiness". BioHarvest Sciences said Olive Cell, an olive-derived plant-cell ingredient, is ready for commercial licensing. It is the second Botanical Synthesis product to reach this stage, after large-scale bioreactor scale-up, manufacturing readiness and a self-affirmed U.S. GRAS process.

Company

About BioHarvest Sciences, Inc.

BioHarvest Sciences Inc. is a biotechnology company focused on Botanical Synthesis, a proprietary platform used to produce plant-based compounds without growing the underlying plant. Its core business centers on developing and commercializing science-based nutraceutical, health, wellness, pharmaceutical, and cosmeceutical solutions, alongside contract development and manufacturing services for third-party partners. The company’s product portfolio includes consumer wellness offerings such as VINIA, a red grape cell supplement, and it also works on plant-derived ingredients for foods, beverages, and specialty applications. BioHarvest Sciences Inc. serves markets spanning dietary supplements, functional foods, health ingredients, and advanced botanical molecules, positioning itself at the intersection of biotechnology and plant-based product innovation. Headquartered in Vancouver, Canada, the company operates with activities in Israel and the United States.

CEO Dr. Zaki Rakib Ph.D. · 89 employees · Canada · https://www.bioharvest.com